PNAS:EBV感染影响你的表观修饰

2019-06-28 海北 MedSci原创

已有的研究显示,爱泼斯坦 - 巴尔病毒(EBV)诱导组蛋白修饰以调节参与EBV驱动的肿瘤发生的信号传导途径。但是迄今为止,我们对于所涉及的监管机制知之甚少。

已有的研究显示,爱泼斯坦 - 巴尔病毒(EBV)诱导组蛋白修饰以调节参与EBV驱动的肿瘤发生的信号传导途径。但是迄今为止,我们对于所涉及的监管机制知之甚少。

在最近的一项研究中,研究人员表明,上皮细胞的EBV感染与异常的组蛋白修饰有关。

具体而言,在永生化鼻咽上皮(NPE)细胞中,异常组蛋白通过降低一组DNA损伤修复成员的启动子区域的转录激活组蛋白标记(H3K4me3)和增强抑制标记(H3K27me3)来完成切换。

在基础切除修复(BER),同源重组,非同源末端连接和错配修复(MMR)途径中的16DNA损伤修复家族成员中,研究人员发现异常的组蛋白二价开关。

在这组DNA修复成员中,在EBV感染NPE细胞中,参与MMRMLH1通过异常的组蛋白二价开关,以启动子高甲基化非依赖性方式显着下调。功能上,MLH1的表达在体外和体内与顺铂敏感性密切相关。

此外,在EBV阳性NPE细胞系中,具有异常组蛋白二价开关的7BER成员以启动子高甲基化非依赖性方式显示出显着富集的通路分析。通过它们在EBV感染的NPE细胞中的下调进一步验证了这一观察结果。

体外彗星和脱嘌呤/脱嘧啶位点测定进一步证实,EBV感染的NPE细胞显示出降低的DNA损伤修复反应性。

这些发现表明EBV相关的异常组蛋白二价转换在宿主细胞中以随后的甲基化非依赖性方式抑制DNA损伤修复基因的重要性。


原始出处:

Leong MML et al. EBV infection is associated with histone bivalent switch modifications in squamous epithelial cells. PNAS, 2019; doi: 10.1073/pnas.1821752116.


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1856319, encodeId=f0251856319c9, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Tue Dec 24 06:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416559, encodeId=871e141655960, content=<a href='/topic/show?id=54d29024251' target=_blank style='color:#2F92EE;'>#表观修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90242, encryptionId=54d29024251, topicName=表观修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab453208753, createdName=wujh_7312820, createdTime=Sun Jun 30 11:18:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480790, encodeId=a2a11480e9072, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Sun Jun 30 11:18:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569363, encodeId=aaa015693637d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Jun 30 11:18:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
    2019-12-24 drwjr
  2. [GetPortalCommentsPageByObjectIdResponse(id=1856319, encodeId=f0251856319c9, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Tue Dec 24 06:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416559, encodeId=871e141655960, content=<a href='/topic/show?id=54d29024251' target=_blank style='color:#2F92EE;'>#表观修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90242, encryptionId=54d29024251, topicName=表观修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab453208753, createdName=wujh_7312820, createdTime=Sun Jun 30 11:18:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480790, encodeId=a2a11480e9072, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Sun Jun 30 11:18:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569363, encodeId=aaa015693637d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Jun 30 11:18:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1856319, encodeId=f0251856319c9, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Tue Dec 24 06:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416559, encodeId=871e141655960, content=<a href='/topic/show?id=54d29024251' target=_blank style='color:#2F92EE;'>#表观修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90242, encryptionId=54d29024251, topicName=表观修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab453208753, createdName=wujh_7312820, createdTime=Sun Jun 30 11:18:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480790, encodeId=a2a11480e9072, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Sun Jun 30 11:18:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569363, encodeId=aaa015693637d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Jun 30 11:18:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1856319, encodeId=f0251856319c9, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Tue Dec 24 06:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416559, encodeId=871e141655960, content=<a href='/topic/show?id=54d29024251' target=_blank style='color:#2F92EE;'>#表观修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90242, encryptionId=54d29024251, topicName=表观修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab453208753, createdName=wujh_7312820, createdTime=Sun Jun 30 11:18:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480790, encodeId=a2a11480e9072, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Sun Jun 30 11:18:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569363, encodeId=aaa015693637d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Jun 30 11:18:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
    2019-06-30 zhangyxzsh

相关资讯

Nat Genet:什么EBV亚型和我国鼻咽癌高风险相关?

已有的研究显示,EBV感染在全世界普遍存在,并且与多种癌症相关,包括鼻咽癌(NPC)。 EBV病毒基因组变异在NPC发展中的重要性及其在中国南方的引人注目的流行病学一直未得到充分研究。

Autophagy:EBV如何损害单核细胞的存活和分化?

据报道,EBV会损害单核细胞体外分化为树突状细胞(DC),并降低细胞存活率。在最近的一项研究中,研究人员为该主题添加了另一层知识,并显示这些效应与巨自噬/自噬,ROS和线粒体生物合成减少相关。

Blood:典型种痘样水疱病样淋巴组织增生性病!

典型种痘样水疱病样淋巴组织增生性病(HVLPD)患者血液T细胞和/或NK细胞中通常携带高水平的EB病毒(EBV) DNA,阳光照射可引起皮肤损伤,损伤的皮肤中有EBV感染的淋巴细胞浸润。虽然HVLPD在美国和欧洲罕见,但在亚洲和南美很常见。该疾病可进展成全身性疾病,导致致死性淋巴瘤。Jeffrey I Cohen等人11年来收治了16位HVLPD患者(美国人和英国人),发现与非白种人相比(5/6)

注意了:EBV相关淋巴增殖性疾病如何鉴别诊断?周剑峰教授有话说!

EBV相关淋巴增殖性疾病在临床上并不多见,表现多样,临床诊断与鉴别具有较大的难度。2017年11月3-5日召开的第四届天津血液肿瘤高峰论坛,来自华中科技大学附属同济医院的周剑锋教授接受了【肿瘤资讯】的采访。周教授介绍了EBV相关淋巴增殖性疾病,并着重回顾了EBV相关淋巴增殖性疾病的诊断与鉴别。

PNAS:EBV增强KSHV诱导淋巴瘤能力

EBV的EBNA-1通过增加KSHV病毒载量和LANA表达在PEL的发病机制中发挥重要作用。

Blood:在骨髓移植后,EBV/LMP特异性T细胞可有效维持EBV相关淋巴瘤的缓解

中心点:供体来源的LMP-Ts可安全用作为辅助疗法来预防EBV相关淋巴瘤在allo-HSCT后复发。LMP-Ts用作辅助疗法时,患者2年总体存活率从68%升高至78%。摘要:以EB病毒(EBV)潜伏膜蛋白(LMPs)为靶点的自体T细胞在标准治疗(包括大剂量化疗+自体干细胞恢复)失败的II型潜伏EBV相关淋巴瘤患者的治疗中显现出安全性和有效性。但是,供体来源的LMP特异性T细胞(LMP-Ts)的安全